|
|
IL15 |
|
Vaxjo ID |
311 |
|
Vaccine Adjuvant Name |
IL15 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
The paper investigates the IL-15-independent maintenance of boosted circulating effector memory CD8 T cells (TEM) and tissue-resident memory CD8 T cells (TRM) and their numerical regulation, challenging previous hypotheses about IL-15 defining memory CD8 T cell capacity. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
IL-15 superagonist receptor-linker-IL-15 (RLI), designed to bypass the need of endogenous IL-15Rα. |
|
Function |
RLI lost effectiveness over time due to accumulation of terminally exhausted PD-1^high TIM-3^+ CD8^+ T cells, which it could not reactivate. Combining RLI with PD-1 blocking antibodies showed synergistic effects, unlike IL-15. RLI induced more memory CD8^+ T cells and stronger effector functions than IL-15. Ex vivo tests on renal cell carcinoma patient samples showed that anti-PD-1 combined with RLI reactivated tumor-infiltrating lymphocytes more effectively than either alone. Overall, the IL-15Rα/IL-15 fusion protein RLI enhances anti-PD-1 therapy and shows promise for boosting antitumor immunity. |
| Related Vaccine(s) |
|
| References |
Schenkel et al., 2016: Schenkel JM, Fraser KA, Casey KA, Beura LK, Pauken KE, Vezys V, Masopust D. IL-15-Independent Maintenance of Tissue-Resident and Boosted Effector Memory CD8 T Cells. Journal of immunology (Baltimore, Md. : 1950). 2016; 196(9); 3920-3926. [PubMed: 27001957].
|
|
